Cliff Asness's NVCR Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 414,742 shares of NovoCure Limited (NVCR) worth $5.36 M, representing 0.00% of the portfolio. First purchased in 2017-Q3, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in NVCR, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 302,351 shares. Largest reduction occurred in Q3 2024, reducing 414,931 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's NovoCure Limited (NVCR) Holding Value Over Time
Track share changes against reported price movement
Quarterly NovoCure Limited (NVCR) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +217,919 | Add 110.72% | 414,742 | $12.93 |
| Q3 2025 | +162,826 | Add 478.94% | 196,823 | $12.92 |
| Q2 2025 | +5,269 | Add 18.34% | 33,997 | $17.80 |
| Q1 2025 | +10,394 | Add 56.69% | 28,728 | $17.82 |
| Q4 2024 | +1,820 | Add 11.02% | 18,334 | $29.80 |
| Q3 2024 | -414,931 | Reduce 96.17% | 16,514 | $15.57 |
| Q2 2024 | +302,351 | Add 234.21% | 431,445 | $17.13 |
| Q1 2024 | -31,247 | Reduce 19.49% | 129,094 | $15.42 |
| Q4 2023 | +130,794 | Add 442.66% | 160,341 | $14.93 |
| Q3 2023 | +29,547 | New Buy | 29,547 | $16.15 |
| Q4 2021 | -4,707 | Sold Out | 0 | $0.00 |
| Q3 2021 | -12,973 | Reduce 73.38% | 4,707 | $116.00 |
| Q2 2021 | -6,669 | Reduce 27.39% | 17,680 | $221.83 |
| Q1 2021 | +13,622 | Add 126.99% | 24,349 | $130.77 |
| Q4 2020 | +10,727 | New Buy | 10,727 | $173.02 |
| Q3 2020 | -82,003 | Sold Out | 0 | $0.00 |
| Q2 2020 | +8,252 | Add 11.19% | 82,003 | $59.30 |
| Q1 2020 | +35,686 | Add 93.75% | 73,751 | $67.33 |
| Q4 2019 | -2,073 | Reduce 5.16% | 38,065 | $84.28 |
| Q3 2019 | +8,239 | Add 25.83% | 40,138 | $74.79 |
| Q2 2019 | -6,658 | Reduce 17.27% | 31,899 | $63.23 |
| Q1 2019 | -4,261 | Reduce 9.95% | 38,557 | $48.16 |
| Q4 2018 | -153,893 | Reduce 78.23% | 42,818 | $33.49 |
| Q3 2018 | -32,399 | Reduce 14.14% | 196,711 | $52.40 |
| Q2 2018 | +52,649 | Add 29.84% | 229,110 | $31.30 |
| Q1 2018 | +10,665 | Add 6.43% | 176,461 | $21.80 |
| Q4 2017 | +140,292 | Add 550.08% | 165,796 | $20.20 |
| Q3 2017 | +25,504 | New Buy | 25,504 | $19.84 |
Cliff Asness's NovoCure Limited Investment FAQs
Cliff Asness first purchased NovoCure Limited (NVCR) in Q3 2017, acquiring 25,504 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held NovoCure Limited (NVCR) for 28 quarters since Q3 2017.
Cliff Asness's largest addition to NovoCure Limited (NVCR) was in Q2 2024, adding 431,445 shares worth $7.39 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 414,742 shares of NovoCure Limited (NVCR), valued at approximately $5.36 M.
As of the Q4 2025 filing, NovoCure Limited (NVCR) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in NovoCure Limited (NVCR) was 431,445 shares, as reported at the end of Q2 2024.